Spectral AI to Feature DeepView® System at 2026 American Burn Association Annual Meeting
Rhea-AI Summary
Spectral AI (Nasdaq: MDAI) will exhibit its DeepView® System at the American Burn Association Annual Meeting, April 14-17, 2026 in Orlando, Booth 601.
The company will offer hands-on demonstrations, an ABA Innovation Theater overview on April 14 at 5:30 pm, and multiple podium and poster presentations. Spectral AI submitted a De Novo 510(k) application for DeepView to the FDA in June 2025.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – MDAIW
On the day this news was published, MDAIW declined 1.54%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Peers show mixed moves: IINNW up 17.65%, PAVMZ down 55%, others flat. This contrasts with MDAIW’s modest 4.11% pre-news gain, pointing to stock-specific dynamics rather than a uniform sector trend.
Previous AI Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 18 | BARDA funding award | Positive | +12.3% | Non-dilutive $31.7M BARDA award to accelerate DeepView® development. |
| Feb 10 | CEO appointment | Positive | +2.2% | New CEO named to guide commercialization of DeepView® burn assessment device. |
| Feb 02 | Awareness campaign | Neutral | -7.3% | Participation in National Burn Awareness Week with ABA partnership and safety outreach. |
| Oct 23 | Capital raise | Neutral | +25.7% | $7.6M equity and warrant financing to fund DeepView® expansion and readiness. |
| Sep 19 | Industry recognition | Positive | +8.0% | Named to TIME’s 2025 World’s Top HealthTech Companies list for AI wound care. |
AI-tagged news has generally seen positive price reactions, with four of five recent AI events moving higher and one awareness-focused item selling off.
Over the last months, Spectral AI’s AI-related updates have centered on DeepView® development and visibility. BARDA funding of $31.7M, leadership changes toward commercialization, a capital raise of $7.6M, and recognition on TIME’s 2025 HealthTech list all supported the commercialization path. Participation in burn-focused campaigns and now the ABA meeting reinforces ongoing engagement with the burn care community as the company awaits FDA decisions on its June 2025 De Novo 510(k) submission.
Historical Comparison
Past AI-tag news for Spectral AI produced an average move of 8.19%, with items spanning funding, recognition, and commercialization milestones, similar in theme to this ABA-focused DeepView® visibility update.
AI-tag history shows a progression from recognition and capital raises to substantial BARDA funding and leadership changes, all supporting DeepView® development and commercialization ahead of the FDA decision.
Market Pulse Summary
This announcement highlights Spectral AI’s continued push to showcase its DeepView® System to burn specialists. Featuring the platform at the ABA meeting, with over 2,200 attendees and an Innovation Theater presentation on April 14, 2026, reinforces prior AI-tag milestones such as BARDA funding and industry recognition. Investors may watch for updates on the June 2025 De Novo 510(k) submission and subsequent clinical adoption signals as DeepView® exposure expands.
Key Terms
multispectral imaging medical
ai algorithm technical
de novo 510(k) regulatory
marketing clearance regulatory
u.s. food and drug administration (fda) regulatory
AI-generated analysis. Not financial advice.
DeepView System will be on Display at Booth #601
DALLAS, April 09, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced its participation in the upcoming Annual Meeting of the American Burn Association, being held April 14-17, 2026 in Orlando, Florida. The Company’s DeepView® System will be on display at Booth 601.
This premier industry event for burn care education, research, and collaboration brings together more than 2,200 clinicians, researchers, and burn care leaders from across the globe.
The theme for this year’s event is “Leading Burn Care into Tomorrow.” To that end, Spectral AI will be:
- Offering a hands-on demonstration of the DeepView System, a predictive diagnostic device and associated software platform that combines multispectral imaging with a proprietary AI algorithm to assess the healing potential of burn wounds. The DeepView System provides clinicians with an immediate, data-driven assessment of whether a burn wound will heal on its own or requires significant medical intervention, enabling earlier and more informed treatment decisions. Spectral AI submitted its De Novo 510(k) marketing clearance application for the DeepView System to the U.S. Food and Drug Administration (FDA) in June 2025.
- Presenting an overview of the DeepView System, including real world experience, at the ABA Innovation Theater on April 14, 2026 at 5:30 pm local time. The event will be hosted by Christopher J. Lewis FRCS (Plast), Consultant Plastic & Reconstructive Surgeon in Newcastle upon Tyne, working within the NHS at the Royal Victoria Infirmary.
The DeepView System will also be included in several podium and poster presentations during the event.
About Spectral AI
Spectral AI, Inc. is a Dallas-based predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns. The Company is working to revolutionize the management of wound care by “Seeing the Unknown®” with its DeepView System. The DeepView System is being developed as a predictive diagnostic device to offer clinicians an objective and immediate assessment of a burn wound’s healing potential prior to treatment or other medical intervention. With algorithm-driven results and a goal of exceeding the current standard of care in the future, the DeepView System is expected to provide fast and accurate treatment insight towards value care by improving patient outcomes and reducing healthcare costs. Spectral AI has been named to TIME’s list of World’s Top HealthTech companies 2025. For more information about the DeepView System, visit www.spectral-ai.com.
Forward-Looking Statements
Certain statements made in this release are “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s strategy, plans, objectives, initiatives and financial outlook. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Company’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. As such, readers are cautioned not to place undue reliance on any forward-looking statements.
Investors should carefully consider the foregoing factors, and the other risks and uncertainties described in the “Risk Factors” sections of the Company’s filings with the US Securities and Exchange Commission, including the Company’s Registration Statement and the other documents filed by the Company. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements.
| Investors: | |
| The Equity Group | |
| Devin Sullivan | Conor Rodriguez |
| Managing Director | Associate |
| dsullivan@theequitygroup.com | crodriguez@theequitygroup.com |
